Edwards Lifesciences (EW) Misses Q2 EPS by 1c, Q3 Revenue Guidance Misses
Get Alerts EW Hot Sheet
Price: $88.40 +0.12%
Revenue Growth %: +8.4%
Financial Fact:
Research and development expenses: 113.1M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: +8.4%
Financial Fact:
Research and development expenses: 113.1M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.4 billion.
GUIDANCE:
Edwards Lifesciences sees Q3 2022 EPS of $0.58-$0.66, versus the consensus of $0.65. Edwards Lifesciences sees Q3 2022 revenue of $1.3-1.37 billion, versus the consensus of $1.44 billion.
For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Qiagen posts $548M in Q3 2026 net sales amid pending EQT deal
- Oceaneering (OII) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share